Core Viewpoint - Bristol Myers Squibb (BMS) has faced challenges over the past five years, including unimpressive financial results and significant patent expirations, but the company may see a turnaround by 2029 if it effectively navigates these challenges [1] Financial Performance - In Q2, BMS reported a revenue increase of nearly 9% year over year, reaching $12.2 billion, marking its best top-line growth in about three years [2] - The best-selling products during this period were Eliquis, generating $3.4 billion in revenue (up 7% year over year), and Opdivo, with sales of $2.4 billion (up 11% year over year), together accounting for 47.6% of total revenue [3] Patent Cliffs and Future Revenue - Both Eliquis and Opdivo are set to lose patent protection by the end of 2029, which is expected to lead to a decline in revenue [3] - BMS anticipates over $25 billion in revenue from its new product portfolio by 2030, supported by ongoing approvals and clinical trials [4] New Product Pipeline - BMS has received several new approvals since 2019, including Reblozyl ($425 million in Q2, 82% growth), Opdualag ($235 million, 53% growth), and Camzyos ($139 million, 202% growth) [4] - A subcutaneous version of Opdivo is expected to target 65% to 75% of its indications in the U.S., helping to mitigate losses from the upcoming patent cliff [5] Investment Outlook - The company's performance is expected to improve over the next five years, with a strong commitment to increasing dividends, having raised payouts for 15 consecutive years [6] - The forward dividend yield is currently at 5.1%, with a conservative cash payout ratio of just under 37%, positioning BMS as a solid blue-chip dividend stock for long-term investment [6]

Investors might want to bet on Bristol Myers Squibb (BMY) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive es ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this biopharmaceutical company have returned +12.2%, compared to the Zacks S&P 500 composite's -2.9% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Bristol Myers falls in, has lost 0.1%. The key question now is: What could be the stoc ...

WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis. “Given their leadership in cell therapy ...

Bristol Myers Squibb Company (BMY) has regained some of the lost territories in the past month, giving anxious investors a ray of hope. This biotech giant has been facing a few challenges for quite some time now.Shares of BMY have risen 16.4% in a month against the industry’s decline of 0.7%. The stock has also outperformed the sector and the S&P 500 in this period.The rally came after the company reported better-than-expected second-quarter results in July. Upside in blood-thinner drug Eliquis and immuno-o ...

JHVEPhoto When I last wrote about the pharmaceuticals company Bristol-Myers Squibb (NYSE:BMY) in June, there appeared little impetus for a price uptick. The company had made a shock earnings outlook downgrade for 2024 following massive acquisition related charges, resulting in an impossibly high forward non-GAAP price-to-earnings (P/E) ratio for the year. This meant that before a re-normalisation of its EPS in 2025, there was little else foreseeable that could surprise about BMY. I was wrong. The stock ...

John Scott/DigitalVision via Getty ImagesDespite lingering skepticism about Bristol-Myers Squibb's future (NYSE:BMY) on Wall Street in recent months, fueled by investor concerns about Eliquis facing patent expirations in 2026, the company pleasantly surprised me with its second-quarter financial results, thanks in part to strong sales in its cardiovascular franchise that offset a muted 11% year-over-year sales growth in its blockbuster PD-1 inhibitor Opdivo due to increasing competition from Merck's Key ...

From a technical perspective, Bristol Myers Squibb (BMY) is looking like an interesting pick, as it just reached a key level of support. BMY recently overtook the 200-day moving average, and this suggests a long-term bullish trend.A useful tool for traders and analysts, the 200-day simple moving average helps determine long-term market trends for stocks, commodities, indexes, and other financial instruments. It moves higher or lower in conjunction with longer-term price performance, and serves as a support ...

gawrav Buying headline-making growth stocks can be fun while they are on their way up. But with so many eyeballs on those names, one has to wonder whether if all the positivity is already baked into the share price, as may be the case with NVIDIA (NVDA) at today’s prices. While it’s great to see a ton of growth in year 1, what if years 2-10 are followed by mediocre returns? Moreover, too high a share price combined with a low dividend yield makes for inadequate return potential through dividend reinvest ...